Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Zemaphyte Phytopharm plc.

H K Wang1

  • 1University of North Carolina at Chapel Hill, Room 302, Beard Hall, School of Pharmacy, Chapel Hill, NC 27599-7360, USA. hwang@gibbs.oit.unc.edu

Idrugs : the Investigational Drugs Journal
|October 4, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[Epidemiology, prevention and control of cervical cancer in middle-aged and elderly women in China].

Zhonghua zhong liu za zhi [Chinese journal of oncology]·2025
Same author

[Clinical analysis of 8 cases of spontaneous cerebrospinal fluid rhinorrhea with aspiration pneumonia].

Zhonghua er bi yan hou tou jing wai ke za zhi = Chinese journal of otorhinolaryngology head and neck surgery·2024
Same author

Species of <i>Botryosphaeriaceae</i> associated with citrus branch diseases in China.

Persoonia·2023
Same author

Proton Shell Evolution below ^{132}Sn: First Measurement of Low-Lying β-Emitting Isomers in ^{123,125}Ag.

Physical review letters·2019
Same author

Diagnostic value of transvaginal color Doppler ultrasound on endometrial lesions.

European journal of gynaecological oncology·2018
Same author

Risk of complications of ultrasound-guided renal biopsy for adult and pediatric patients with systemic lupus erythematosus.

Lupus·2018
Same journal

Filibuvir, a non-nucleoside NS5B polymerase inhibitor for the potential oral treatment of chronic HCV infection.

IDrugs : the investigational drugs journal·2010
Same journal

Remimazolam, a short-acting GABA(A) receptor agonist for intravenous sedation and/or anesthesia in day-case surgical and non-surgical procedures.

IDrugs : the investigational drugs journal·2010
Same journal

LX-1031, a tryptophan 5-hydroxylase inhibitor that reduces 5-HT levels for the potential treatment of irritable bowel syndrome.

IDrugs : the investigational drugs journal·2010
Same journal

Dexpramipexole, the R(+) enantiomer of pramipexole, for the potential treatment of amyotrophic lateral sclerosis.

IDrugs : the investigational drugs journal·2010
Same journal

Lu-AA21004, a multimodal serotonergic agent, for the potential treatment of depression and anxiety.

IDrugs : the investigational drugs journal·2010
Same journal

Florbetapir (18F), a PET imaging agent that binds to amyloid plaques for the potential detection of Alzheimer's disease.

IDrugs : the investigational drugs journal·2010
See all related articles

Zemaphyte, a Chinese herbal extract, shows promise as a novel therapy for severe atopic eczema. Further development is underway by Phytopharm to assess its efficacy.

Area of Science:

  • Dermatology
  • Pharmacology
  • Phytomedicine

Background:

  • Atopic eczema is a chronic inflammatory skin condition with limited effective treatments.
  • Current therapies for severe atopic eczema often have side effects or limited efficacy.
  • There is a need for novel therapeutic approaches for managing severe atopic eczema.

Purpose of the Study:

  • To introduce Zemaphyte, a Chinese herbal extract, as a potential new treatment for severe atopic eczema.
  • To highlight the ongoing development of Zemaphyte by Phytopharm.

Main Methods:

  • The abstract does not specify methods.
  • The development of Zemaphyte is mentioned.

Main Results:

  • The abstract does not specify results.

Related Experiment Videos

  • Zemaphyte is identified as a potential therapy.

    • Conclusions:

    • Zemaphyte, a Chinese herbal extract, is a candidate for treating severe atopic eczema.
    • Phytopharm is developing Zemaphyte for therapeutic use.